Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material ... Jan 02
The results also show that opaganib inhibits SARS-CoV-2 virus replication and proinflammatory markers in relevant preclinical models ... Dec 17
The data will be further analyzed to determine any potential impact on other studies of ruxolitinib in patients with COVID-19, and will be submitted ... Dec 15
PureTech’s global, randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate the efficacy, safety and tolerability of LYT-100 in adults ... Dec 05
Zydus Cadila, had received an approval from the Drugs Controller General of India to start the Phase 3 clinical trial in COVID-19 patients with ... Dec 04
This test may help identify recovering patients who could potentially be serum and plasma donors for developing treatments for COVID-19... Dec 03
ARCA believes that AB201 is the only anticoagulant class new chemical entity in development for COVID-19 that has a Fast Track designation... Nov 24
The independent, pre-programmed DSMB unanimously recommends the continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia... Nov 23
The clinical evidence from Regeneron's outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis ... Nov 23
Bamlanivimab received emergency use authorization (EUA) from the U.S. Food and Drug Administration on November 9, 2020... Nov 23
Monoclonal antibody leads for COVID-19: A way forward In combating COVID-19 ... Nov 19
Researchers say, fluvoxamine may be having beneficial effects by some other mechanism not yet understood... Nov 17
Eli Lilly’s neutralizing antibody bamlanivimab receives US FDA emergency use authorization for the treatment of recently diagnosed COVID-19... Nov 12
Celltrion launches post-exposure prophylaxis clinical trial of anti-COVID-19 monoclonal antibody treatment candidate, CT-P59 ... Oct 15
-Advertisements-
Thursday, May 16, 2024
